EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate

Author： Uz Burak   Buyukasik Yahya   Atay Hilmi   Kelkitli Engin   Turgut Mehmet   Bektas Ozlen   Eliacik Eylem   Isik Ayşe   Aksu Salih   Goker Hakan   Sayinalp Nilgun   Ozcebe Osman I.   Haznedaroglu Ibrahim C.  

Publisher： Maney Publishing

ISSN： 1024-5332

Source： Hematology, Vol.18, Iss.5, 2013-09, pp. : 247-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of lower dose of imatinib to CML patients

By Horikoshi A.   Takei K.   Sawada S.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1167-1167

Elsevier

Access to resources Recommend Favorite

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

By Lee Yoo  

International Journal of Hematology, Vol. 97, Iss. 6, 2013-06 ,pp. : 804-807

Springer Publishing Company

Access to resources Recommend Favorite

Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate

By Sonmez Mehmet   Akagun Tulin   Cobanoglu Umit   Topbas Murat   Erkut Nergiz   Yilmaz Mustafa   Ovali Ercument   Omay Serdar Bedii  

Hematology, Vol. 14, Iss. 4, 2009-08 ,pp. : 220-223

Maney Publishing

Access to resources Recommend Favorite

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study

By Usuki Kensuke  

International Journal of Hematology, Vol. 95, Iss. 4, 2012-04 ,pp. : 409-419

Springer Publishing Company

Access to resources Recommend Favorite

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

By Ritchie D.   Seymour J.   Grigg A.   Roberts A.   Hoyt R.   Thompson S.   Szer J.   Prince H.  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 101-105

Springer Publishing Company

Access to resources Recommend Favorite